Free Trial
NASDAQ:NEO

NeoGenomics (NEO) Stock Price, News & Analysis

NeoGenomics logo
$9.09 -1.01 (-10.00%)
Closing price 03/10/2025 04:00 PM Eastern
Extended Trading
$9.26 +0.17 (+1.82%)
As of 03/10/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About NeoGenomics Stock (NASDAQ:NEO)

Key Stats

Today's Range
$9.08
$9.97
50-Day Range
$9.09
$18.61
52-Week Range
$8.98
$19.12
Volume
1.65 million shs
Average Volume
781,481 shs
Market Capitalization
$1.17 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.60
Consensus Rating
Moderate Buy

Company Overview

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Remove Ads

NeoGenomics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
73rd Percentile Overall Score

NEO MarketRank™: 

NeoGenomics scored higher than 73% of companies evaluated by MarketBeat, and ranked 289th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    NeoGenomics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    NeoGenomics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about NeoGenomics' stock forecast and price target.
  • Earnings Growth

    Earnings for NeoGenomics are expected to grow in the coming year, from ($0.20) to $0.09 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NeoGenomics is -14.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NeoGenomics is -14.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    NeoGenomics has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about NeoGenomics' valuation and earnings.
  • Percentage of Shares Shorted

    2.71% of the float of NeoGenomics has been sold short.
  • Short Interest Ratio / Days to Cover

    NeoGenomics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NeoGenomics has recently decreased by 9.02%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    NeoGenomics does not currently pay a dividend.

  • Dividend Growth

    NeoGenomics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.71% of the float of NeoGenomics has been sold short.
  • Short Interest Ratio / Days to Cover

    NeoGenomics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in NeoGenomics has recently decreased by 9.02%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    NeoGenomics has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for NeoGenomics this week, compared to 4 articles on an average week.
  • MarketBeat Follows

    Only 1 people have added NeoGenomics to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, NeoGenomics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.30% of the stock of NeoGenomics is held by insiders.

  • Percentage Held by Institutions

    98.50% of the stock of NeoGenomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about NeoGenomics' insider trading history.
Receive NEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter.

NEO Stock News Headlines

NeoGenomics acquires Pathline, terms undisclosed
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
NeoGenomics: Decent Fundamentals, But Still Overvalued
Piper Sandler Remains a Buy on NeoGenomics (NEO)
NeoGenomics price target lowered to $18 from $21 at Piper Sandler
BTIG Sticks to Their Buy Rating for NeoGenomics (NEO)
See More Headlines

NEO Stock Analysis - Frequently Asked Questions

NeoGenomics' stock was trading at $16.48 on January 1st, 2025. Since then, NEO shares have decreased by 44.8% and is now trading at $9.09.
View the best growth stocks for 2025 here
.

NeoGenomics, Inc. (NASDAQ:NEO) announced its quarterly earnings data on Tuesday, February, 18th. The medical research company reported ($0.02) earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by $0.05. The medical research company earned $172 million during the quarter, compared to analyst estimates of $173.40 million. NeoGenomics had a negative trailing twelve-month return on equity of 2.10% and a negative net margin of 11.92%.

The following companies are subsidiaries of NeoGenomics: Inivata Limited, Trapelo Health, Genesis Acquisition Holding Corp, Genoptix, Clarient Inc, GE Medical Holding AB., Path Labs LLC, and more.

NeoGenomics' top institutional shareholders include Vanguard Group Inc. (11.09%), T. Rowe Price Investment Management Inc. (5.09%), Janus Henderson Group PLC (4.80%) and Brown Advisory Inc. (4.80%).
View institutional ownership trends
.

Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NeoGenomics investors own include Humana (HUM), American Water Works (AWK), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR) and AUO (AUOTY).

Company Calendar

Last Earnings
2/18/2025
Today
3/11/2025
Next Earnings (Estimated)
4/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Testing laboratories
Sub-Industry
Business Services
Current Symbol
NASDAQ:NEO
Employees
2,100
Year Founded
2002

Price Target and Rating

Average Stock Price Target
$19.60
High Stock Price Target
$26.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+115.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
10 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-87,970,000.00
Pretax Margin
-12.21%

Debt

Sales & Book Value

Annual Sales
$660.57 million
Cash Flow
$0.34 per share
Price / Cash Flow
27.03
Book Value
$7.02 per share
Price / Book
1.29

Miscellaneous

Free Float
126,791,000
Market Cap
$1.17 billion
Optionable
Optionable
Beta
1.28

Social Links

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:NEO) was last updated on 3/11/2025 by MarketBeat.com Staff
From Our Partners